

INTERNATIONAL E-WORKSHOP
FRAGILE X & ASSOCIATED CONDITIONS
MARCH 18TH & 19TH 2021 - ONLINE

In collaboration with its **Scientific Board,** and in partnership with **DéfiScience** (the National Network for Intellectual Disabilities), the **Fragile X France association** (*www.xfra.org*) is proud to announce its next **international workshop** dedicated to the **Fragile X Syndrome and premutation associated conditions.**

This collaborative working meeting aims to connect **researchers & clinicians** working on Fragile X syndrome in order to **consolidate or bring out new therapeutic leads**.

Given the still uncertain health context, the Workshop on Fragile X is organized online.

PROGRAM

THURSDAY MARCH, 18TH

10 a.m. to 1 p.m. : Clinical update

Clinical genetics in 2020 ***(Delphine Héron)***

Clinical follow up for Fragile X ***(Vincent des Portes)***

Impact on daily life ***(Fragile X France)***

Impact on daily life : DIXIT study ***(Aurore Curie & Clémentine Fort)***

FXTAS ***(Perrine Charles)***

FXPOI ***(Anne Bachelot)***

2 p.m. to 5 p.m. : Physiopathology of Fragile X Syndrome

FMRP : function, molecular targets, mouse models ***(Hervé Moine)***

Neurobiology of FXTAS and therapeutic approaches ***(Nicolas Charlet Berguerand)***

Neurobiology of Fragile X : revolution of iPS and organoides ***(Peng Jin)***

Modeling Fragile X Syndrome with iPSCs ***(Cecilia Laterza)***

FRIDAY MARCH, 19TH

10 a.m. to 1 p.m. : Therapeutics of Fragile X Syndrome

What therapeutic trial plans ? ***(Aurore Curie)***

Efficacy judgment criteria in Fragile X ***(Aurore Curie & Perrine Charles)***

Identification of non-invasive clinical markers of FXS ***(Sylvain Briault)***

Fragile X : 30 years later : satisfactions, worries, expectations ***(Fragile X France)***

Fragile X : 30 years of research ***(Jean-Louis Mandel - subject to change)***

2 p.m. to 5 p.m. : Innovative therapies, drug candidates

Therapeutic trials stopped & in progress, what lessons ? ***(Sébastien Jacquemont - subject to change)***

DGKK gene therapy for Fragile X treatment : the GETEX project ***(Hervé Moine)***

Therapeutic Potential of CRISPR/Cas9 Mediated Deletion of CGG repeats for FMR1 Gene Reactivation in Fragile X Syndrome ***(Daman Kumari)***

Involvement of Phosphodiesterase 2A Activity : a new treatment for Fragile X Syndrome and other forms of neuronal development disease ***(Barbara Bardoni)***

5 p.m. to 5:15 p.m. : Conclusion

INFORMATIONS

PUBLIC

Clinicians & Researchers

All discussions in English

DATES

March 18th & 19th, 2021

From 10 a.m. to 1 p.m.

And from 2 p.m. to 5 p.m.

REGISTRATIONS

Registration required

Possible until march 17th, 2021

www.xfra.org

www.defiscience.fr

PRICES

Free registration

CONTACT

For any further information or comments, please contact us at :

contact@xfra.org

+33 6 25 45 64 96

With the support of :